Neurocrine Biosciences (NBIX) EBT Margin (2010 - 2026)
Neurocrine Biosciences (NBIX) posted EBT Margin of 30.3% for Q1 2026, up 1.95% on a QoQ basis from 29.72% in Q4 2025, and up 2773.0% year-over-year from 1.05% in Q1 2025.
Neurocrine Biosciences (NBIX) EBT Margin (2010 - 2026) Analysis & Trends
Neurocrine Biosciences' EBT Margin history runs 16 years deep, the most recent figure standing at 30.3% for Q1 2026.
- Quarterly EBT Margin rose 2773.0% year-over-year to 30.3% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 30.22% (up 1089.0% YoY) and the FY2025 annual result came in at 24.66%, up 403.0% from the prior year.
- EBT Margin was 30.3% for Q1 2026 at Neurocrine Biosciences, up from 29.72% in the prior quarter.
- Across five years, EBT Margin topped out at 38.47% in Q4 2023 and bottomed at 116.5% in Q2 2022.
- A 5-year average of 12.39% and a median of 25.24% in 2022 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin sank 13640 bps — and 2023, when it jumped 14336 bps.
- Neurocrine Biosciences' EBT Margin stood at 28.62% in 2022, then surged by 34 bps to 38.47% in 2023, then sank by 33 bps to 25.9% in 2024, then rose by 15 bps to 29.72% in 2025, then rose by 2 bps to 30.3% in 2026.
- Business Quant data shows NBIX's EBT Margin at 30.3% in Q1 2026, 29.72% in Q4 2025, and 36.71% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 10.97% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 33.51% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -41.57% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 40.73% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -7.05% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 30.30% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.35% |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | -3.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.30% |
| Dec 31, 2025 | 29.72% |
| Sep 30, 2025 | 36.71% |
| Jun 30, 2025 | 23.20% |
| Mar 31, 2025 | 2.57% |
| Dec 31, 2024 | 25.90% |
| Sep 30, 2024 | 30.59% |
| Jun 30, 2024 | 16.71% |
| Mar 31, 2024 | 6.70% |
| Dec 31, 2023 | 38.47% |
| Sep 30, 2023 | 23.18% |
| Jun 30, 2023 | 26.86% |
| Mar 31, 2023 | -24.57% |
| Dec 31, 2022 | 28.62% |
| Sep 30, 2022 | 25.24% |
| Jun 30, 2022 | -116.50% |
| Mar 31, 2022 | 6.89% |
| Dec 31, 2021 | -4.42% |
| Sep 30, 2021 | 10.30% |
| Jun 30, 2021 | 19.90% |